SEC Filing Summary: Carlyle Group Inc. (Form 13F)
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Carlyle Group Inc. for the reporting period ending June 30, 2024. The document discloses the investment manager's holdings in equity securities as of the quarter-end date. It does not contain financial performance data for Carlyle Group Inc. itself, but rather a snapshot of its portfolio positions.
Key Financial Metrics and Portfolio Composition
The filing lists 30 specific equity positions. The total value of these disclosed holdings is not explicitly summed in the text, but individual position values range from approximately $14,800 to over $382 million. Key observations include:
- Largest Position by Value: Quidelortho Corp ($382,719,348).
- Largest Position by Share Count: Quidelortho Corp (11,520,751 shares).
- Significant Holdings: ZoomInfo Technologies Inc ($220,215,419), Soleno Therapeutics Inc ($166,364,023), and GDS Holdings Ltd ($37,834,677).
- Investment Authority: All listed positions are reported with "Sole" voting authority, indicating Carlyle Group Inc. has full discretion over these shares.
- Asset Classes: The portfolio includes common stock, sponsored American Depositary Shares (ADS), and shares of companies in the biotechnology, technology, and consumer sectors.
Material Changes and Comparisons
The filing text provided does not contain data for the prior comparable period (March 31, 2024). Therefore, no analysis of material changes, net purchases, or sales versus the previous quarter can be derived from this specific input.
Guidance, Risks, and Contingencies
As a Form 13F, this document is a regulatory disclosure of holdings and does not include management commentary, forward-looking guidance, risk factors, or contingency plans. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the total aggregate value of the portfolio by summing the "Value" column, as the filing lists individual positions but not a grand total.
- Compare these June 30, 2024 holdings against the March 31, 2024 Form 13F to identify new entries (e.g., Effector Therapeutics, Exicure) and exited positions.
- Review the "Other" column for footnotes (e.g., "2,3" for GDS Holdings and Meta Data) to understand if these positions involve derivatives or other complex structures.
- Confirm the "Sole" voting authority status to ensure no shared control arrangements exist for these specific tickers.